
HDC finds ‘critical systems failure' at Health NZ, following woman's delayed cancer diagnosis and subsequent death
'There appears to be a failure in the referral system, along with us not knowing better about the aggressive nature and severity of gynaecological cancers since no one receives education or awareness on this ...' the family said in its complaint.
'If the referral was actioned when it should have [been], I believe we could have saved my mum's life. We're providing this feedback in hopes that this does not happen to another family again.'
The HDC found Health New Zealand Te Whatu Ora Te Toka Tumai Auckland had a systems failure, where a referral made by the woman's GP did not get entered into the appropriate database.
There was no electronic interface between the Referral Management System (RMS), where the GP's e-referral arrived, and the Radiology Information System (RIS), which would have triggered an ultrasound appointment.
At the time of events, the process involved a referral being printed by one staff member, and entered and scanned by another staff member.
Health NZ acknowledged those staff carried out other reception and administration duties at the same time, and 'there was no reconciliation process in place to check that the referrals that had been received in RMS had been loaded into RIS'.
HDC Deputy Commissioner Vanessa Caldwell said the case demonstrated a 'critical systems issue' at Health NZ.
'[Health NZ] failed to implement adequate measures to prevent patient harm caused by the lack of systems integration ... it did not recognise the clinical risk created by the lack of support provided to new staff.'
The HDC said Health NZ had been aware of the 'systems limitation' and had 'acknowedged there was no safety-net in place'.
It was 'regrettable' that the data entry error made by the booking and reception administration led to 'a significant delay in the provision of care to Ms A', the HDC found.
After the consultant gastroenterologist spotted the right-sided pelvic mass, which appeared solid, lobulated and separate from the uterus, he asked Ms A's GP to make referrals for a pelvic ultrasound and a gynaecological appointment.
The GP, referred to as Dr B in the HDC findings, made those two referrals, via an electronic process, with both forms labelled 'urgent', and noting the incidental finding of the mass.
Dr B did receive an email from gynaecology, requesting Ms A undergo blood tests for biomarkers, as there was 'insufficient information to triage the referral'.
However, Dr B did not request the additional tumour markers as he believed it would be 'redundant' and 'unnecessary'. He was under a 'reasonable impression' that Ms A would qualify for an urgent gynaecology clinic appointment, based on the existing findings, including the large mass.
Advertisement Advertise with NZME.
His failure to complete the additional requested tumour markers constituted 'a mild departure' from the accepted standard of practice, the HDC found, given those markers had a limited role in the diagnosis of ovarian malignancy.
Although Dr B explained his clinical reasoning for his decision, Dr Caldwell was critical that he did not seek clarification when he was unwilling to order the additional tests.
When the woman visited on an unrelated matter a couple of months later, he asked his receptionist to clarify the wait time for the ultrasound scan.
'Dr B said that they were not given any specific indication other than a 'long wait', and the radiology staff did not give any indication that the referral was not in their system,' the findings said.
After two weeks of abdominal bloating and pain, four weeks of constipation, and two days of vomiting, Ms A was referred to hospital where it was found the pelvic mass had progressed in size, and she was diagnosed with advanced ovarian cancer.
Ms A wanted to travel to China to see her parents and receive treatment, however, she wasn't cleared to fly given the 'risk of a sudden event leading to her death' and a life expectancy that was 'limited to weeks to months'.
Advertise with NZME.
The tumour did not respond to chemotherapy, surgery wasn't an option due to the progression of the cancer, and Ms A passed away a month after entering end-of-life care.
The HDC found the GP's management of the referral also 'constituted a mild departure from the accepted standard of practice'.
'... it is important for primary-care providers to track referrals to secondary care and provide updated referral information when relevant, to ensure that management is undertaken in a timely manner,' the findings stated.
It was noted that it was 'unclear whether [formal] tracking would have altered Ms A's outcome', given the scheduling of the first gynaecology specialist appointment was dependent on receipt of the ultrasound referral.
Advice to the HDC said Ms A's delayed diagnosis was due to process failures and inefficiencies in secondary care, as opposed to an oversight by Dr B.
However, Dr Caldwell reminded Dr B that as the access point to secondary care, GPs should follow up referrals and ensure that appropriate action has been taken.
She encouraged him to act proactively and with a degree of urgency when managing patient referrals, particularly when a life-threatening disease is involved.
Both Dr B and Health NZ apologised to the family of Ms A.
Health NZ is making ongoing changes to integration between systems, and there are now weekly reports that allow for cross-referencing to ensure referrals have been entered.
There are dedicated booking clerks for primary care referral, who do not have the additional responsibility of working reception, and do the task at a dedicated time where there are minimal distractions.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Scoop
4 days ago
- Scoop
Multiple Sclerosis Prevalence On The Sharp Increase: Study
Press Release – University of Auckland The number of people diagnosed with multiple sclerosis (MS) in New Zealand increased by a third between 2006 and 2022, according to research from the University of Auckland. The prevalence of multiple sclerosis in New Zealand has sharply risen since 2006, especially in some communities, according to a University of Auckland study. Lead author Dr Natalia Boven, a postdoctoral fellow from the University's COMPASS Research Centre, says the study found the MS prevalence rate had climbed to 96.6 per 100,000 people as of June 2022, an increase from 72.4 per 100,000 in 2006. 'And notably, while European New Zealanders are being diagnosed with MS at a higher rate (132.4 per 100,000), we found MS increased substantially for Māori, Pacific peoples and Asian ethnic groups over the same period,' she says. Boven says Māori rates rose from 15.0 per 100,000 to 33.1 per 100,000 in 2022, the Pacific rate rose to 9.2 per 100,000 and the Asian ethnic group rate increased to 16.0 per 100,000. 'And of concern is the data shows people living in more deprived areas were less likely to be diagnosed with MS,' says Boven. 'This pattern was more pronounced for Māori and Pacific peoples, which suggests they may face barriers accessing services to receive a MS diagnosis.' As a social scientist, she says more research is needed to find out whether this is the case, and what the barriers might be, as an early diagnosis can make all the difference in terms of delaying disease progression and therefore improving quality of life. Experts agree that multiple sclerosis is a manageable and treatable condition in most cases, especially with early diagnosis. Recently published in the New Zealand Medical Journal, the study was backed by Multiple Sclerosis New Zealand (MSNZ). National manager Amanda Rose says patients regularly report the biggest barriers to diagnosis are a lack of MS awareness in the community, and critical shortages of specialistservices which can delay diagnosis from a couple of weeks to as long as several years in some instances. 'Too many New Zealanders face delays in being diagnosed with MS due to limited access to specialist neurologist appointments and MRI scans,' says Rose. 'The longstanding shortage of neurologists in Aotearoa has created long waiting lists for many people with neurological conditions, including MS. We've been advocating for over ten years to increase our number of neurologists, with little to no progress.' The study used the Stats NZ Integrated Data Infrastructure (IDI) and included anonymous data from hospitalisations, disability support, pharmaceutical dispensing of MS treatments and needs assessments. To build on the study's findings and support targeted advocacy for those with the condition, Multiple Sclerosis New Zealand has now contracted University researchers at COMPASS to expand their scope. They will again be using IDI data to explore the demographic and socioeconomic characteristics of people living with MS in Aotearoa; including geographic distribution, education, income, and employment history, access to disability support, allied healthcare, and income support. Identifying multiple sclerosis in linked administrative health data in Aotearoa New Zealand New Zealand Medical Journal.


Scoop
4 days ago
- Scoop
Multiple Sclerosis Prevalence On The Sharp Increase: Study
Press Release – University of Auckland The study found the MS prevalence rate had climbed to 96.6 per 100,000 people as of June 2022, an increase from 72.4 per 100,000 in 2006., Lead author Dr Natalia Boven, a postdoctoral fellow from the Universitys COMPASS Research Centre, says. The number of people diagnosed with multiple sclerosis (MS) in New Zealand increased by a third between 2006 and 2022, according to research from the University of Auckland. The prevalence of multiple sclerosis in New Zealand has sharply risen since 2006, especially in some communities, according to a University of Auckland study. Lead author Dr Natalia Boven, a postdoctoral fellow from the University's COMPASS Research Centre, says the study found the MS prevalence rate had climbed to 96.6 per 100,000 people as of June 2022, an increase from 72.4 per 100,000 in 2006. 'And notably, while European New Zealanders are being diagnosed with MS at a higher rate (132.4 per 100,000), we found MS increased substantially for Māori, Pacific peoples and Asian ethnic groups over the same period,' she says. Boven says Māori rates rose from 15.0 per 100,000 to 33.1 per 100,000 in 2022, the Pacific rate rose to 9.2 per 100,000 and the Asian ethnic group rate increased to 16.0 per 100,000. 'And of concern is the data shows people living in more deprived areas were less likely to be diagnosed with MS,' says Boven. 'This pattern was more pronounced for Māori and Pacific peoples, which suggests they may face barriers accessing services to receive a MS diagnosis.' As a social scientist, she says more research is needed to find out whether this is the case, and what the barriers might be, as an early diagnosis can make all the difference in terms of delaying disease progression and therefore improving quality of life. Experts agree that multiple sclerosis is a manageable and treatable condition in most cases, especially with early diagnosis. Recently published in the New Zealand Medical Journal, the study was backed by Multiple Sclerosis New Zealand (MSNZ). National manager Amanda Rose says patients regularly report the biggest barriers to diagnosis are a lack of MS awareness in the community, and critical shortages of specialistservices which can delay diagnosis from a couple of weeks to as long as several years in some instances. 'Too many New Zealanders face delays in being diagnosed with MS due to limited access to specialist neurologist appointments and MRI scans,' says Rose. 'The longstanding shortage of neurologists in Aotearoa has created long waiting lists for many people with neurological conditions, including MS. We've been advocating for over ten years to increase our number of neurologists, with little to no progress.' The study used the Stats NZ Integrated Data Infrastructure (IDI) and included anonymous data from hospitalisations, disability support, pharmaceutical dispensing of MS treatments and needs assessments. To build on the study's findings and support targeted advocacy for those with the condition, Multiple Sclerosis New Zealand has now contracted University researchers at COMPASS to expand their scope. They will again be using IDI data to explore the demographic and socioeconomic characteristics of people living with MS in Aotearoa; including geographic distribution, education, income, and employment history, access to disability support, allied healthcare, and income support.


Scoop
4 days ago
- Scoop
Multiple Sclerosis Prevalence On The Sharp Increase: Study
The number of people diagnosed with multiple sclerosis (MS) in New Zealand increased by a third between 2006 and 2022, according to research from the University of Auckland. The prevalence of multiple sclerosis in New Zealand has sharply risen since 2006, especially in some communities, according to a University of Auckland study. Lead author Dr Natalia Boven, a postdoctoral fellow from the University's COMPASS Research Centre, says the study found the MS prevalence rate had climbed to 96.6 per 100,000 people as of June 2022, an increase from 72.4 per 100,000 in 2006. 'And notably, while European New Zealanders are being diagnosed with MS at a higher rate (132.4 per 100,000), we found MS increased substantially for Māori, Pacific peoples and Asian ethnic groups over the same period," she says. Boven says Māori rates rose from 15.0 per 100,000 to 33.1 per 100,000 in 2022, the Pacific rate rose to 9.2 per 100,000 and the Asian ethnic group rate increased to 16.0 per 100,000. 'And of concern is the data shows people living in more deprived areas were less likely to be diagnosed with MS,' says Boven. 'This pattern was more pronounced for Māori and Pacific peoples, which suggests they may face barriers accessing services to receive a MS diagnosis.' As a social scientist, she says more research is needed to find out whether this is the case, and what the barriers might be, as an early diagnosis can make all the difference in terms of delaying disease progression and therefore improving quality of life. Experts agree that multiple sclerosis is a manageable and treatable condition in most cases, especially with early diagnosis. Recently published in the New Zealand Medical Journal, the study was backed by Multiple Sclerosis New Zealand (MSNZ). National manager Amanda Rose says patients regularly report the biggest barriers to diagnosis are a lack of MS awareness in the community, and critical shortages of specialistservices which can delay diagnosis from a couple of weeks to as long as several years in some instances. 'Too many New Zealanders face delays in being diagnosed with MS due to limited access to specialist neurologist appointments and MRI scans,' says Rose. 'The longstanding shortage of neurologists in Aotearoa has created long waiting lists for many people with neurological conditions, including MS. We've been advocating for over ten years to increase our number of neurologists, with little to no progress.' The study used the Stats NZ Integrated Data Infrastructure (IDI) and included anonymous data from hospitalisations, disability support, pharmaceutical dispensing of MS treatments and needs assessments. To build on the study's findings and support targeted advocacy for those with the condition, Multiple Sclerosis New Zealand has now contracted University researchers at COMPASS to expand their scope. They will again be using IDI data to explore the demographic and socioeconomic characteristics of people living with MS in Aotearoa; including geographic distribution, education, income, and employment history, access to disability support, allied healthcare, and income support. by Natalia Boven, Deborah Mason, Barry Milne, Anna Ranta, Andrew Sporle, Lisa Underwood, Julie Winter-Smith, and Vanessa Selak is published in the 28 March edition of the New Zealand Medical Journal.